Previous 10 | Next 10 |
home / stock / bayry / bayry news
Sigilon Therapeutics has filed proposed terms for its $101 million U.S. IPO. The firm is advancing programs to treat blood, lysosomal storage and other diseases. SGTX has produced a positive initial result with its first trial patient, has a strong collaboration relationship with ...
Our three-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further a...
Sigilon Therapeutics has filed to raise capital via an IPO. The firm is developing treatments for blood disorders and other diseases. SGTX has produced intriguing preclinical study results for its lead candidate for the treatment of Hemophilia A. For further details see: ...
One of the best things about a democracy is getting to vote out representatives who let us down. As shareholders, it's much harder to express dissatisfaction in management without just selling shares, since you may really like the business despite management. But some investors might ...
The European Medicines Agency's advisory group CHMP has adopted positive opinions backing extended uses of the following drugs:Amgen's (AMGN) Kyprolis (carfilzomib): in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone or with dexamethasone alone for the trea...
The Q3/2020 earnings season kicked off and lifted markets across the board. I am continuing my monthly investment plans and suspiciously follow the massive rally in technology stocks as well as the vaccine-driven rebound in value stocks. My dividend income amounted to $290.44, dow...
The following slide deck was published by Bayer Aktiengesellschaft in conjunction with this event. For further details see: Bayer (BAYRY) Presents At Morgan Stanley Global Chemicals And Ag Conference - Slideshow
Bayer (BAYRY) has made substantial progress in resolving tens of thousands of remaining claims that its Roundup weedkiller causes cancer, court appointed mediator Kenneth Feinberg says.Feinberg spoke via Zoom at a hearing in San Francisco federal court, where a judge still oversees nearly 2,0...
Like every week on my TEV blog, I want to show you some stocks that will go ex-dividend in the next few days. I'll also review a few companies currently in the focus of investors or that have an attractive fundamental valuation. Additionally, I'll give you some insights into my re...
Compugen has concentrated exposure to immuno-oncology, where it has formed key collaborations with large players in early-stage studies. Shareholders have seen +119% upside YTD; however, accurate valuation is difficult at present due to uncertainty of future cash flows and pipeline co...
News, Short Squeeze, Breakout and More Instantly...
Bayer AG ADR Company Name:
BAYRY Stock Symbol:
OTCMKTS Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...